Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06094140 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer

Study acronym: NEO-IMPACT
StatusActive, Not Recruiting
PhasePhase 2
Started2022-05-20
View on ClinicalTrials.gov ↗
To determine the safety and tolerability of adding durvalumab to mFOLFIRINOX prior to surgery in patients with resectable or borderline resectable pancreatic adenocarcinoma.

Amendment record

Amended 2 times since 2023-10-19; most recent filed 2026-05-05. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-05-05
Amendment Study Status v2
2024-11-28
Amendment Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v1
2023-10-19
Original filing
Trial Details
NCT Number NCT06094140
Lead Sponsor Australasian Gastro-Intestinal Trials Group
Collaborators: The University of New South Wales, Walter and Eliza Hall Institute of Medical Research
Conditions Pancreatic Cancer
Enrollment 20 participants
Start Date 2022-05-20
Primary Completion 2024-06-30 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-06